Highly specialized Team
Lumos has recruited a highly specialized team across all tiers of the business — Board, Leadership, Operations, and advisers — who are committed to driving innovation and commercial traction in the point-of-care diagnostics industry.
Sam Lanyon
Non-Executive Chair
Read profile
Sam Lanyon
Non-Executive Chair
Sam Lanyon has more than 25 years of experience in strategy, sales and operations with a demonstrated track record in the global commercialization of technology rich healthcare products.
Mr. Lanyon currently serves as Executive Director and co-founder of Planet Innovation and a Non-Executive Director of Paragon Funds Management. He also serves as a Non-Executive Director of Visus Therapeutics, a clinical-stage company focused on developing innovative medicines to improve vision.
Previously, Mr. Lanyon held international executive roles with Leica Microsystems, part of Danaher Corporation, and ASX listed Vision Systems Ltd where he was responsible for establishing Vision Biosystem's sales, marketing, and service operations throughout the EU, Middle East, Latin America, and Asia Pacific.
Mr. Lanyon holds an Honors degree in Mechanical Engineering from the University of Melbourne, a Post Graduate Diploma in Management from Melbourne Business School and has completed strategy training from London Business School.
Mr. Lanyon currently serves as Executive Director and co-founder of Planet Innovation and a Non-Executive Director of Paragon Funds Management. He also serves as a Non-Executive Director of Visus Therapeutics, a clinical-stage company focused on developing innovative medicines to improve vision.
Previously, Mr. Lanyon held international executive roles with Leica Microsystems, part of Danaher Corporation, and ASX listed Vision Systems Ltd where he was responsible for establishing Vision Biosystem's sales, marketing, and service operations throughout the EU, Middle East, Latin America, and Asia Pacific.
Mr. Lanyon holds an Honors degree in Mechanical Engineering from the University of Melbourne, a Post Graduate Diploma in Management from Melbourne Business School and has completed strategy training from London Business School.
Bronwyn Le Grice
Non-Executive Director
Read profile
Bronwyn Le Grice
Non-Executive Director
Bronwyn Le Grice has more than 18 years of executive experience in the health technology sector spanning commercialization, venture capital, corporate development, capital raising and industry advocacy.
Formerly an Investment Director with leading healthcare investment firm, BioScience Managers, Ms. Le Grice managed over $65M of private and public equity capital raisings and was actively involved in over $30M of portfolio investments.
In 2017, she founded ANDHealth, Australia's only dedicated digital health accelerator and commercialization support organization which has led to significant growth within Australia's nascent digital health sector. Ms. Le Grice holds a number of health, technology and innovation advisory roles both in Australia and internationally.
Ms. Le Grice has a Masters of Commercial Law from the University of Melbourne and a Bachelor of Commerce from the University of Western Australia.
Formerly an Investment Director with leading healthcare investment firm, BioScience Managers, Ms. Le Grice managed over $65M of private and public equity capital raisings and was actively involved in over $30M of portfolio investments.
In 2017, she founded ANDHealth, Australia's only dedicated digital health accelerator and commercialization support organization which has led to significant growth within Australia's nascent digital health sector. Ms. Le Grice holds a number of health, technology and innovation advisory roles both in Australia and internationally.
Ms. Le Grice has a Masters of Commercial Law from the University of Melbourne and a Bachelor of Commerce from the University of Western Australia.
Lawrence Mehren
Non-Executive Director
Read profile
Lawrence Mehren
Non-Executive Director
Lawrence Mehren served as President and Chief Executive Officer as well as a Director of Accelerate Diagnostics from 2012 to 2020. During his tenure, the company developed and launched its groundbreaking Accelerate Pheno™ instrument.
Prior to this, Mr. Mehren was the Head of Global Business for Ventana Medical Systems and Roche Tissue Diagnostics, managing its four business units. He also held various global leadership positions with Ventana including Senior Vice President of Emerging Businesses and Chief Financial Officer. Mr. Mehren was also Managing Director, Partner and Head of P&M Corporate Finance's life sciences practice.
Mr. Mehren holds an MBA from Northwestern University's Kellogg Graduate School of Management and a BA in Political Science from the University of Arizona.
Prior to this, Mr. Mehren was the Head of Global Business for Ventana Medical Systems and Roche Tissue Diagnostics, managing its four business units. He also held various global leadership positions with Ventana including Senior Vice President of Emerging Businesses and Chief Financial Officer. Mr. Mehren was also Managing Director, Partner and Head of P&M Corporate Finance's life sciences practice.
Mr. Mehren holds an MBA from Northwestern University's Kellogg Graduate School of Management and a BA in Political Science from the University of Arizona.
Catherine Robson
Non-Executive Director
Read profile
Catherine Robson
Non-Executive Director
Catherine Robson has more than 25 years of experience in management, finance and investment.
Ms. Robson currently serves as a Non-Executive Director for ASX listed Equity Trustees (EQT Holdings Limited), where she is the chair of the Risk Committee and chair of subsidiary entity Equity Trustees Superannuation Limited.
Ms. Robson's other Board appointments include serving as a non-executive director and chair of the Audit Committee of NGM Group, one of Australia's largest customer owned banking groups, operating the Greater Bank and Newcastle Permanent Building Society Brands. She is also a non-executive director and chair of the Audit and Risk Committee of the Australian Business Growth Fund and is chair of Korowa Anglican Girls School Council.
Ms. Robson holds a Master of Laws, majoring in Tax, from Melbourne University as well as a Bachelor of Laws and BA in Asian Studies from The Australian National University. She has a Graduate Diploma in Applied Finance and is a graduate of the Australian Institute of Company Directors Course.
Ms. Robson currently serves as a Non-Executive Director for ASX listed Equity Trustees (EQT Holdings Limited), where she is the chair of the Risk Committee and chair of subsidiary entity Equity Trustees Superannuation Limited.
Ms. Robson's other Board appointments include serving as a non-executive director and chair of the Audit Committee of NGM Group, one of Australia's largest customer owned banking groups, operating the Greater Bank and Newcastle Permanent Building Society Brands. She is also a non-executive director and chair of the Audit and Risk Committee of the Australian Business Growth Fund and is chair of Korowa Anglican Girls School Council.
Ms. Robson holds a Master of Laws, majoring in Tax, from Melbourne University as well as a Bachelor of Laws and BA in Asian Studies from The Australian National University. She has a Graduate Diploma in Applied Finance and is a graduate of the Australian Institute of Company Directors Course.
Doug Ward
Chief Executive Officer and Managing Director
Read profile
Doug Ward
Chief Executive Officer and Managing Director
Doug Ward has more than 30 years of medical device and diagnostics experience at notable global healthcare companies including Roche, GE, Siemens, Bayer, Chiron and Hologic. Mr. Ward was named CEO of Lumos Diagnostics in June 2022 and is leveraging his industry experience and empowering leadership approach to guide Lumos Diagnostics through an exciting time of unlimited potential growth.
During his career, Mr. Ward has held executive positions where he developed and implemented novel business strategies and introduced transformational products to the practice of medicine.
Prior to joining Lumos, he served as Vice President, Strategy and Business Development at Hologic where he led a global team responsible for fostering innovation in women's healthcare to improve clinical results.
Mr. Ward also served as the CEO of Personal Genome Diagnostics (PGDx) where he led the organization's transformation from a clinical laboratory testing service into a fully functional molecular invitro diagnostics (IVD) company.
With a deep understanding of the life sciences ecosystem, Mr. Ward excels at setting the strategic direction for global companies. He brings experience across all company functions, including Commercial Leadership, R&D, Operations, Quality, Regulatory, Service, and Support.
Mr. Ward earned his Bachelor of Arts in Pre-medicine Studies from Ohio Wesleyan University.
During his career, Mr. Ward has held executive positions where he developed and implemented novel business strategies and introduced transformational products to the practice of medicine.
Prior to joining Lumos, he served as Vice President, Strategy and Business Development at Hologic where he led a global team responsible for fostering innovation in women's healthcare to improve clinical results.
Mr. Ward also served as the CEO of Personal Genome Diagnostics (PGDx) where he led the organization's transformation from a clinical laboratory testing service into a fully functional molecular invitro diagnostics (IVD) company.
With a deep understanding of the life sciences ecosystem, Mr. Ward excels at setting the strategic direction for global companies. He brings experience across all company functions, including Commercial Leadership, R&D, Operations, Quality, Regulatory, Service, and Support.
Mr. Ward earned his Bachelor of Arts in Pre-medicine Studies from Ohio Wesleyan University.
Doug Ward
Chief Executive Officer and Managing Director
Read profile
Doug Ward
Chief Executive Officer and Managing Director
Doug Ward has more than 30 years of medical device and diagnostics experience at notable global healthcare companies including Roche, GE, Siemens, Bayer, Chiron and Hologic. Mr. Ward was named CEO of Lumos Diagnostics in June 2022 and is leveraging his industry experience and empowering leadership approach to guide Lumos Diagnostics through an exciting time of unlimited potential growth.
During his career, Mr. Ward has held executive positions where he developed and implemented novel business strategies and introduced transformational products to the practice of medicine. Prior to joining Lumos, he served as Vice President, Strategy and Business Development at Hologic where he led a global team responsible for fostering innovation in women's healthcare to improve clinical results.
Mr. Ward also served as the CEO of Personal Genome Diagnostics (PGDx) where he led the organization's transformation from a clinical laboratory testing service into a fully functional molecular invitro diagnostics (IVD) company.
With a deep understanding of the life sciences ecosystem, Mr. Ward excels at setting the strategic direction for global companies. He brings experience across all company functions, including Commercial Leadership, R&D, Operations, Quality, Regulatory, Service, and Support.
Mr. Ward earned his Bachelor of Arts in Pre-medicine Studies from Ohio Wesleyan University.
During his career, Mr. Ward has held executive positions where he developed and implemented novel business strategies and introduced transformational products to the practice of medicine. Prior to joining Lumos, he served as Vice President, Strategy and Business Development at Hologic where he led a global team responsible for fostering innovation in women's healthcare to improve clinical results.
Mr. Ward also served as the CEO of Personal Genome Diagnostics (PGDx) where he led the organization's transformation from a clinical laboratory testing service into a fully functional molecular invitro diagnostics (IVD) company.
With a deep understanding of the life sciences ecosystem, Mr. Ward excels at setting the strategic direction for global companies. He brings experience across all company functions, including Commercial Leadership, R&D, Operations, Quality, Regulatory, Service, and Support.
Mr. Ward earned his Bachelor of Arts in Pre-medicine Studies from Ohio Wesleyan University.
Sacha Dopheide, PhD
Chief Technology Officer
Read profile
Sacha Dopheide, PhD
Chief Technology Officer
Sacha Dopheide, PhD has more than 20 years of experience in the in vitro diagnostic device industry, ranging from point-of-care devices to laboratory analyzers.
She currently serves as the company's Chief Technology Officer and has held an executive leadership role within Lumos Diagnostics since 2017.
Dr. Dopheide has experience managing the full product development process for immunoassays and their accompanying electronic readers from proof of concept through development, verification and external validation trials.
Dr. Dopheide has taken a leading role in identification and due diligence of M&A targets and integration activities.
She also leads the Lumos Diagnostic service business unit's business development activities, including directly conducting global market research, establishing partnerships and generating strategic product roadmaps for new tests.
Dr. Dopheide holds a BSc (Hons) and PhD from Monash University.
She currently serves as the company's Chief Technology Officer and has held an executive leadership role within Lumos Diagnostics since 2017.
Dr. Dopheide has experience managing the full product development process for immunoassays and their accompanying electronic readers from proof of concept through development, verification and external validation trials.
Dr. Dopheide has taken a leading role in identification and due diligence of M&A targets and integration activities.
She also leads the Lumos Diagnostic service business unit's business development activities, including directly conducting global market research, establishing partnerships and generating strategic product roadmaps for new tests.
Dr. Dopheide holds a BSc (Hons) and PhD from Monash University.
Barrie Lambert
Chief Financial Officer
Read profile
Barrie Lambert
Chief Financial Officer
Barrie Lambert has more than 20 years of international experience in high growth companies from the medical device research and development services and manufacturing sector, as well as technology, retail, ecommerce, consumer goods and business services.
Prior to joining Lumos Diagnostics, Mr. Lambert was the Chief Financial Officer of Planet Innovation, one of the founding shareholders and current major shareholder of Lumos. In that role, he was a member of the executive team helping to grow Planet Innovation fourfold, completing several capital raises, financing, and merger and acquisition transactions.
Mr. Lambert's previous roles have included Chief Financial Officer and President & Chief Executive Officer of technology businesses with operations in Australia, United States, New Zealand and United Kingdom. He also spent more than six years as Chief Financial Officer, Vice President of Operations, then as the Vice President and General Manager of Sephora.com, a business unit of Louis Vuitton Moet Hennessy.
Mr. Lambert has a broad background in governance, strategy, finance, M&A, operations, technology and sales, which have allowed him to drive positive change by partnering with the Executive Team and Board of Directors to set and execute strategy, deliver quality customer service and create value.
His qualifications include a BA in Accounting from the University of South Australia, Chartered Accountant from the Australian Institute of Chartered Accountants, MBA from the Graduate School of Business, University of Sydney, and a graduate of the Australian Institute of Company Directors.
Prior to joining Lumos Diagnostics, Mr. Lambert was the Chief Financial Officer of Planet Innovation, one of the founding shareholders and current major shareholder of Lumos. In that role, he was a member of the executive team helping to grow Planet Innovation fourfold, completing several capital raises, financing, and merger and acquisition transactions.
Mr. Lambert's previous roles have included Chief Financial Officer and President & Chief Executive Officer of technology businesses with operations in Australia, United States, New Zealand and United Kingdom. He also spent more than six years as Chief Financial Officer, Vice President of Operations, then as the Vice President and General Manager of Sephora.com, a business unit of Louis Vuitton Moet Hennessy.
Mr. Lambert has a broad background in governance, strategy, finance, M&A, operations, technology and sales, which have allowed him to drive positive change by partnering with the Executive Team and Board of Directors to set and execute strategy, deliver quality customer service and create value.
His qualifications include a BA in Accounting from the University of South Australia, Chartered Accountant from the Australian Institute of Chartered Accountants, MBA from the Graduate School of Business, University of Sydney, and a graduate of the Australian Institute of Company Directors.
Paul Kase
Chief Commercial Officer
Read profile
Paul Kase
Chief Commercial Officer
Paul Kase brings more than 28 years of medical sales and leadership experience in the point-of-care diagnostic testing market to Lumos Diagnostics.
As the Senior Vice President of Commercial Operations, he is responsible for leading worldwide commercial sales efforts, while implementing marketing strategies focused on revenue growth, building strong customer partnerships, and generating end-user demand and adoption for a portfolio of products.
Mr. Kase is a proven leader in coaching and developing best-in-class sales teams that consistently meet and exceed revenue goals.
His experience also extends to overseeing customer and technical support divisions, commercial product launches, key opinion leader development, and the creation of distributor networks in the hospital and primary care markets.
Mr. Kase earned his Bachelors in Economics and English from Bucknell University.
As the Senior Vice President of Commercial Operations, he is responsible for leading worldwide commercial sales efforts, while implementing marketing strategies focused on revenue growth, building strong customer partnerships, and generating end-user demand and adoption for a portfolio of products.
Mr. Kase is a proven leader in coaching and developing best-in-class sales teams that consistently meet and exceed revenue goals.
His experience also extends to overseeing customer and technical support divisions, commercial product launches, key opinion leader development, and the creation of distributor networks in the hospital and primary care markets.
Mr. Kase earned his Bachelors in Economics and English from Bucknell University.
Sue Hibbeln
Vice President of Quality and Regulatory Affairs
Read profile
Sue Hibbeln
Vice President of Quality and Regulatory Affairs
Sue Hibbeln has more than 20 years in Regulatory Affairs and Quality Assurance at start-up, mid- and large-sized companies for a variety of medical devices, including in vitro diagnostic devices, software, hardware, implants and sutures.
She currently serves as the company's Vice President of Quality and Regulatory Affairs. Ms. Hibbeln specializes in global strategy, registration, regulatory/cultural intelligence and quality systems. Her passion for working with diverse cultures has enabled opportunities to work with world-class talent on global cross-functional teams.
Ms. Hibbeln especially enjoys helping clients with global remediation and harmonization efforts and monitors direction from the International Medical Device Regulators Forum (IMDRF) and World Health Organization (WHO).
Ms. Hibbeln is a CMMI Practitioner and a certified appraisal team member (ATM) for the Medical Device Discovery Appraisal Program (MDDAP) – a joint initiative for FDA, MDIC, and ISACA.
Ms. Hibbeln earned a BA from LaSalle University, a MS in Regulatory Affairs from San Diego State University and a Regulatory Affairs Certification (RAC) through the Regulatory Affairs Professionals Society (RAPS). She also completed the Kellogg Executive Leadership Program at Northwestern University.
She currently serves as the company's Vice President of Quality and Regulatory Affairs. Ms. Hibbeln specializes in global strategy, registration, regulatory/cultural intelligence and quality systems. Her passion for working with diverse cultures has enabled opportunities to work with world-class talent on global cross-functional teams.
Ms. Hibbeln especially enjoys helping clients with global remediation and harmonization efforts and monitors direction from the International Medical Device Regulators Forum (IMDRF) and World Health Organization (WHO).
Ms. Hibbeln is a CMMI Practitioner and a certified appraisal team member (ATM) for the Medical Device Discovery Appraisal Program (MDDAP) – a joint initiative for FDA, MDIC, and ISACA.
Ms. Hibbeln earned a BA from LaSalle University, a MS in Regulatory Affairs from San Diego State University and a Regulatory Affairs Certification (RAC) through the Regulatory Affairs Professionals Society (RAPS). She also completed the Kellogg Executive Leadership Program at Northwestern University.
Sarah Glubka
Vice President of Human Resources
Read profile
Sarah Glubka
Vice President of Human Resources
Sarah Glubka brings over 19 years of strategic HR leadership to driving success across diverse industries like biotech, healthcare, and energy. She's passionate about cultivating thriving company cultures and empowering high-performing teams.
Throughout her career, Ms. Glubka has excelled in translating HR initiatives that drive performance and employee engagement. Her role extends beyond traditional HR functions, as she has been instrumental in training, developing, and providing strategic HR guidance and support to leadership across all aspects of HR. She is recognized for her ability to resolve complex organizational challenges through people-related solutions.
A trusted advisor and collaborator, Ms. Glubka excels at working with executives and stakeholders at all levels. Her problem-solving skills and ability to navigate complex situations are highly valued.
Ms. Glubka earned a Master's Degree in Human Resource Management from National University and a BS in Business Management from the University of Phoenix.
Throughout her career, Ms. Glubka has excelled in translating HR initiatives that drive performance and employee engagement. Her role extends beyond traditional HR functions, as she has been instrumental in training, developing, and providing strategic HR guidance and support to leadership across all aspects of HR. She is recognized for her ability to resolve complex organizational challenges through people-related solutions.
A trusted advisor and collaborator, Ms. Glubka excels at working with executives and stakeholders at all levels. Her problem-solving skills and ability to navigate complex situations are highly valued.
Ms. Glubka earned a Master's Degree in Human Resource Management from National University and a BS in Business Management from the University of Phoenix.
Annie Bell
Vice President of Medical Affairs
Read profile
Annie Bell
Vice President of Medical Affairs
Annie Bell has more than 15 years of professional experience in the medical device and in vitro diagnostic industry including direct patient management, medical education and clinical study management.
Currently serving as the Sr. Director of Medical Affairs for Lumos Diagnostics, Ms. Bell is a strategic leader with a passion for simplifying challenging diagnostic dilemmas for patients and clinicians.
She has expertise in clinical trial scientific methodology and operational oversight including early feasibility studies, usability studies, CLIA Waiver studies, registration trials, and post-market interventional/cost-effectiveness studies.
Ms. Bell holds a BS from Pennsylvania State University, a MS from Rush University Chicago, IL, and completed a post-graduate Global Clinical Trial Research Program with Harvard Medical School, Boston MA. Ms. Bell is a Board-certified Neonatal Nurse Practitioner.
Currently serving as the Sr. Director of Medical Affairs for Lumos Diagnostics, Ms. Bell is a strategic leader with a passion for simplifying challenging diagnostic dilemmas for patients and clinicians.
She has expertise in clinical trial scientific methodology and operational oversight including early feasibility studies, usability studies, CLIA Waiver studies, registration trials, and post-market interventional/cost-effectiveness studies.
Ms. Bell holds a BS from Pennsylvania State University, a MS from Rush University Chicago, IL, and completed a post-graduate Global Clinical Trial Research Program with Harvard Medical School, Boston MA. Ms. Bell is a Board-certified Neonatal Nurse Practitioner.
Jon Gary
Vice President of Research and Development
Read profile
Jon Gary
Vice President of Research and Development
Jon Gary, Ph.D. has more than 15 years of experience in in vitro diagnostic product development.
His scientific expertise includes antibody design and development, assay optimization across a range of biomedical platforms, as well as new technology investigations. Jon oversees project and product development activities as well as assisting in early-stage Business Development opportunities.
Jon holds a B.A. (with Honors) in Biology from Northwestern University. He received his Ph.D. in Molecular Biology in 1997 from the University of California, Los Angeles and conducted his post-doctoral research at the University of California, San Diego.
During his academic training, Jon has received Awards or Fellowships from the National Institutes of Health, Howard Hughes Medical Institute, and American Cancer Society.
His scientific expertise includes antibody design and development, assay optimization across a range of biomedical platforms, as well as new technology investigations. Jon oversees project and product development activities as well as assisting in early-stage Business Development opportunities.
Jon holds a B.A. (with Honors) in Biology from Northwestern University. He received his Ph.D. in Molecular Biology in 1997 from the University of California, Los Angeles and conducted his post-doctoral research at the University of California, San Diego.
During his academic training, Jon has received Awards or Fellowships from the National Institutes of Health, Howard Hughes Medical Institute, and American Cancer Society.
Mike Raymundo
Vice President of Product Development
Read profile
Mike Raymundo
Vice President of Product Development
Mike Raymundo is a seasoned leader with over 23 years of experience in the in vitro diagnostics industry.
His passion lies in translating scientific breakthroughs into tangible diagnostic solutions. Mike excels in leading the entire product development lifecycle, with a particular focus on ensuring a smooth transition from development to full-scale manufacturing.
Mike's expertise extends beyond the laboratory. He possesses a deep understanding of manufacturing processes and plays a vital role in overseeing product transfer. This ensures that assays developed in the lab can be efficiently and cost-effectively produced at scale. His leadership fosters a collaborative environment where scientists, engineers, and manufacturing teams work seamlessly to bring new diagnostics to market.
Mike's proven track record includes successfully transferring numerous diagnostic assays to manufacturing, ensuring consistent quality and regulatory compliance. He leverages his strong communication skills to bridge the gap between R&D and manufacturing, resulting in a streamlined and efficient product launch process.
His passion lies in translating scientific breakthroughs into tangible diagnostic solutions. Mike excels in leading the entire product development lifecycle, with a particular focus on ensuring a smooth transition from development to full-scale manufacturing.
Mike's expertise extends beyond the laboratory. He possesses a deep understanding of manufacturing processes and plays a vital role in overseeing product transfer. This ensures that assays developed in the lab can be efficiently and cost-effectively produced at scale. His leadership fosters a collaborative environment where scientists, engineers, and manufacturing teams work seamlessly to bring new diagnostics to market.
Mike's proven track record includes successfully transferring numerous diagnostic assays to manufacturing, ensuring consistent quality and regulatory compliance. He leverages his strong communication skills to bridge the gap between R&D and manufacturing, resulting in a streamlined and efficient product launch process.
Anthony Favaloro
Vice President of Operations
Read profile
Anthony Favaloro
Vice President of Operations
Anthony Favaloro has more than 17 years of experience working in design, sales, and operational roles within the in vitro diagnostics and medical device industry.
Anthony currently serves as the Vice President of Operations at Lumos Diagnostics overseeing operational activities including the manufacturing and supply chain functions as well as assisting in early-stage Business Development opportunities.
Anthony has experience leading large, multi-disciplinary teams to conceptualize commercially viable core technology through development, manufacturing transfer, post-launch operations and sustainment. He prioritizes communication, transparency and cross-functional collaboration to maximize quality outcomes for all stakeholders.
Anthony earned an Honors degree in Electrical Engineering as well as a Bachelor of Biomedical Science, majoring in Biochemistry and Physiology, from The University of Melbourne.
Anthony currently serves as the Vice President of Operations at Lumos Diagnostics overseeing operational activities including the manufacturing and supply chain functions as well as assisting in early-stage Business Development opportunities.
Anthony has experience leading large, multi-disciplinary teams to conceptualize commercially viable core technology through development, manufacturing transfer, post-launch operations and sustainment. He prioritizes communication, transparency and cross-functional collaboration to maximize quality outcomes for all stakeholders.
Anthony earned an Honors degree in Electrical Engineering as well as a Bachelor of Biomedical Science, majoring in Biochemistry and Physiology, from The University of Melbourne.